ARPO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARPO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aerpio Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2021 was $-4.77 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2021 was $-20.63 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aerpio Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2021 was -15,903.33%. Aerpio Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -25,276.82%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aerpio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -30.32%.
The historical data trend for Aerpio Pharmaceuticals's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aerpio Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||
EBIT | Get a 7-Day Free Trial | -16.63 | -21.30 | -11.18 | -22.44 | -6.28 |
Aerpio Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | |
EBIT | Get a 7-Day Free Trial | 9.26 | -5.86 | -5.64 | -4.37 | -4.77 |
For the Biotechnology subindustry, Aerpio Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aerpio Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aerpio Pharmaceuticals's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aerpio Pharmaceuticals (NAS:ARPO) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Aerpio Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2021 is calculated as:
ROC % (Q: Jun. 2021 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Mar. 2021 ) | + | Invested Capital (Q: Jun. 2021 )) | / count ) |
= | -19.084 * ( 1 - 0% ) | / | ( (0.20099999999999 | + | 0.038999999999994) | / 2 ) |
= | -19.084 | / | 0.11999999999999 | |||
= | -15,903.33 % |
where
Invested Capital | (Q: Mar. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 41.161 | - | 2.09 | - | ( 39.009 | - | max(0, 2.129 | - | 40.999 | + | 39.009 | )) |
= | 0.20099999999999 |
Invested Capital | (Q: Jun. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 37.424 | - | 2.198 | - | ( 36.816 | - | max(0, 2.208 | - | 37.395 | + | 36.816 | )) |
= | 0.038999999999994 |
Note: The Operating Income data used here is four times the quarterly (Jun. 2021) data.
2. Joel Greenblatt's definition of Return on Capital:
Aerpio Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:
ROC (Joel Greenblatt) % | (Q: Jun. 2021 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Mar. 2021 | Q: Jun. 2021 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -19.084 | / | ( ( (0.142 + max(-0.099999999999998, 0)) | + | (0.009 + max(-1.619, 0)) ) | / | 2 ) |
= | -19.084 | / | ( ( 0.142 | + | 0.009 ) | / | 2 ) |
= | -19.084 | / | 0.0755 | ||||
= | -25,276.82 % |
where Working Capital is:
Working Capital | (Q: Mar. 2021 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0 | + | 0 | + | 1.99) | - | (2.09 | + | 0 | + | 0) |
= | -0.099999999999998 |
Working Capital | (Q: Jun. 2021 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0 | + | 0 | + | 0.579) | - | (2.198 | + | 0 | + | 4.4408920985006E-16) |
= | -1.619 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Aerpio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Jun. 2021 ) |
= | -20.634 | / | 68.047 | |
= | -30.32 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Aerpio Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Pravin Dugel | director | C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242 |
Caley Castelein | director | THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104 |
Anupam Dalal | director | 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108 |
Cheryl Cohen | director | C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105 |
Steven Prelack | director | 7 WHEELWRIGHT ROAD, MEDFIELD MA 02052 |
Regina Marek | officer: Vice President of Finance | C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI OH 45242 |
Joseph H. Gardner | director, officer: President | C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242 |
Kevin G. Peters | officer: See Remarks | C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, C OH 45242 |
Muneer A Satter | director, 10 percent owner | C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
Chau Quang Khuong | director, 10 percent owner | C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Michael W Rogers | officer: See Remarks | C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210 |
Stephen J Hoffman | director, officer: Chief Executive Officer | C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301 |
Novartis Bioventures Ltd | 10 percent owner | C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000 |
Ag Novartis | 10 percent owner | LICHTSTRASSE 35, BASEL V8 CH 4056 |
From GuruFocus
By Marketwired Marketwired • 11-06-2020
By Marketwired Marketwired • 08-11-2021
By Marketwired Marketwired • 08-26-2021
By Marketwired Marketwired • 01-06-2021
By Marketwired Marketwired • 06-04-2021
By Marketwired Marketwired • 03-05-2021
By PRNewswire PRNewswire • 05-20-2021
By PRNewswire PRNewswire • 05-27-2021
By Business Wire Business Wire • 05-18-2021
By PRNewswire PRNewswire • 05-27-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.